Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04876599 · ClinicalTrials.gov registry record · NA

Mind-body Resiliency Intervention for Fear of Cancer Recurrence

A NA study of Cancer and Coping Skills, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
64
Enrollment target
5
Study locations

NCT04876599 is a NA study of Cancer and Coping Skills that has completed, run by Massachusetts General Hospital. The registered enrollment target is 64 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04876599, a NA study of Cancer and Coping Skills, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to test the feasibility of a virtual, group mind-body resiliency intervention adapted to target fear of recurrence (FOR) among cancer survivors.

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL IN FOCUS

Study Locations (5)

Massachusetts

  • Massachusett General Hospital Cancer Center - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Mass General at Emerson Hospital -- Bethke - Concord
  • Mass General/North Shore Cancer Center - Danvers
  • Newton-Wellesley Hospital - Newton

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2021-07-09
Est. Completion 2023-08-31
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT04876599

The ClinicalTrials.gov registry entry for NCT04876599 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT04876599 reports 5 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04876599 about?

NCT04876599 is a clinical study titled "Mind-body Resiliency Intervention for Fear of Cancer Recurrence". The purpose of this study is to test the feasibility of a virtual, group mind-body resiliency intervention adapted to target fear of recurrence (FOR) among cancer survivors.

What is the current status of trial NCT04876599?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2021-07-09. Estimated completion is 2023-08-31.

What conditions does trial NCT04876599 study?

This clinical trial studies the following conditions: Cancer, Coping Skills, Coping Behavior.

What interventions are being tested in trial NCT04876599?

The interventions under investigation include: Usual Care (BEHAVIORAL), IN FOCUS (BEHAVIORAL).

Who is sponsoring clinical trial NCT04876599?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04876599 being conducted?

This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.